Deprescribing recommendations_an essential consideration for clinical guideline developers.pdf (762.79 kB)
0/0

Deprescribing recommendations: an essential consideration for clinical guideline developers

Download (762.79 kB)
journal contribution
posted on 10.06.2020 by Frank Moriarty, Kevin Pottie, Lisa Dolovich, Lisa McCarthy, Carlos Rojas-Fernandez, Barbara Farrell

One area of focus of the Bruyère Evidence-Based Deprescribing Guidelines Symposium held in March 2018 was encouraging the routine inclusion of deprescribing recommendations in clinical guidelines. Clinical guidelines often do not accommodate frailty or patients with multiple comorbid conditions. This can give rise to complex medication regimens and risk of medication harm. Despite monitoring and stopping treatment being a key part of rational prescribing, deprescribing is often overlooked in general and in the context of guidelines. There are several challenges to increasing deprescribing recommendations in clinical guidelines. These include limited evidence on the effects of deprescribing, lack of awareness among guideline developers, potential conflicts of interest, and lack of incentives for deprescribing research. To date, medicines regulators, payers, governments, and journals have not encouraged the inclusion of deprescribing recommendations in guidelines. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system could address some of these challenges through its focus on values and preferences, distinct rating of quality of evidence and strength of recommendations, downgrading quality due to indirect evidence, and an explicit approach to conflicts of interest. Further work to adapt GRADE methods to deprescribing could be of benefit. Establishing deprescribing recommendations as a routine part of clinical guidelines is an important opportunity to improve evidence-based clinical practice, and ultimately, patient care.

Funding

Funding for the planning and implementation of the symposium was provided by a Knowledge Mobilization Partnership Program grant through the Centre for Aging and Brain Health Innovation. Additional financial support was provided by the Bruyère Centre for Learning, Research and Innovation, the Canadian Foundation for Healthcare Improvement, CADTH, Medical Pharmacies, and the Canadian Deprescribing Network.

History

Comments

This article is also available at www.sciencedirect.com

Published Citation

Moriarty F, Pottie K, Dolovich L, McCarthy L, Rojas-Fernandez C, Farrell B. Deprescribing Recommendations: An Essential Consideration for Clinical Guideline Developers. Research in Social and Administrative Pharmacy. 2019;15(6):806-810

Publication Date

18/09/2018

PubMed ID

30241877

Exports

Logo branding

Exports